'The name was inaccurate': PCOS gets a new name after years-long effort

Polycystic ovary syndrome has been renamed after a concerted effort by researchers and clinicians to address a longstanding misnomer in medical terminology. The condition, which affects roughly 8-13% of reproductive-age women worldwide, will now be called reproductive and metabolic dysfunction.

The previous name proved problematic because it emphasized ovarian cysts, which appear in some patients but are neither required for diagnosis nor central to the condition's pathophysiology. Many women with PCOS lack polycystic ovaries entirely, yet still experience the hormonal and metabolic disruptions that define the syndrome.

The new terminology reflects what clinicians have known for decades. PCOS involves insulin resistance, elevated androgen levels, irregular menstruation, infertility, and metabolic complications including increased risk of type 2 diabetes. These systemic features extend far beyond ovarian morphology. The misleading name created diagnostic delays and hindered research into the condition's true mechanisms.

Medical organizations including the American College of Obstetricians and Gynecologists have adopted the updated name following years of consultation with endocrinologists, reproductive specialists, and patient advocacy groups. The shift represents a broader move within medicine to establish diagnostic criteria based on underlying pathology rather than imaging findings.

Renaming established diseases remains rare in modern medicine, requiring consensus across multiple specialties and regulatory bodies. Similar efforts to rename conditions have faced resistance from clinicians accustomed to traditional terminology. However, PCOS researchers argue the new name will improve patient outcomes by directing attention toward metabolic interventions and preventing underdiagnosis in women who lack obvious ovarian changes on ultrasound.

The condition's complex presentation has spawned multiple diagnostic frameworks. The Rotterdam criteria, widely used internationally, defines PCOS through any two of three features: ovulatory dysfunction, elevated androgens, and polycystic ovarian morphology